Stroke Disorder and Treatment Market Forecast (2023-2032): Exploring Key Drivers, Challenges, and Regional Variations
The Stroke Disorder and Treatment Market Size was valued at USD 20.5 billion in 2022 and is projected to grow from USD 22.11 Billion in 2023 to USD 40.63 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% during the forecast period (2023 - 2032).
The
global market for stroke disorder and treatment is witnessing substantial
growth as the prevalence of strokes continues to rise globally. Factors such as
an aging population, sedentary lifestyles, and increasing incidence of risk
factors like hypertension contribute to the increasing burden of stroke
disorders. This has led to a surge in research and development activities aimed
at advancing treatment options and improving patient outcomes.
Ischemic stroke,
accounting for the majority of stroke cases, has driven the development of
innovative thrombolytic and anticoagulant therapies to dissolve or prevent
blood clots. Hemorrhagic stroke, while less common, requires specialized
treatments to manage bleeding and minimize damage to the brain.
The
Stroke Disorder and Treatment Market is a dynamic and evolving sector focused
on addressing the complexities of ischemic and hemorrhagic strokes, two
distinct types of stroke disorders. Ischemic stroke occurs when blood flow to
the brain is blocked, leading to a lack of oxygen and nutrients. On the other
hand, hemorrhagic stroke results from a ruptured blood vessel, causing bleeding
within the brain. Both conditions require immediate medical attention and
comprehensive treatment strategies.
The
market is witnessing a paradigm shift towards personalized medicine, with a focus
on precision diagnostics and targeted therapies. Advancements in imaging
technologies, such as magnetic resonance imaging (MRI) and computed tomography
(CT), enable early and accurate diagnosis, facilitating prompt intervention.
Key
players in the stroke disorder and treatment market are investing in research
collaborations, clinical trials, and strategic partnerships to bring novel
therapies and interventions to market. These initiatives aim to not only
enhance patient care but also address the economic and social impact of
stroke-related disabilities.
Market Regions
The
regional segmentation of global stroke disorder and treatment market cover
North America, Europe, and the Asia Pacific. The key players of this market are
primarily based in these continents. In other parts of the world, the market
for stroke disorder and treatment is limited due to less advanced medical
facilities, little investment in health care, lack of awareness about stroke
disorder, and poor infrastructure. In North America and Europe, investments in
research and development (R & D) and advanced medical facilities boost this
market. According to this report, the market in North America is expected to
rise and earn maximum revenue by the end of the forecast period. Europe is the
second largest market. The Asia Pacific is expected to be the fastest growing
market for stroke disorder and treatment because some countries in this region
do have advanced medical facilities.
Key Players
The
global stroke disorder and
treatment companies include AstraZeneca {United Kingdom (UK)}, Bayer Pharma AG
(Germany), Daiichi Sankyo (Japan), Novartis AG (Switzerland), and Pfizer
{United States of America (US)}.
Market Segmentation
The
global stroke disorder and treatment market has been segmented into medicines,
treatment, types, and lastly region. Based on medicines, this market has been
segmented into anticoagulants, anti-hypertensive, and antiplatelet.
Anticoagulants, also called blood thinners, are chemical substances that
prevent or reduce coagulation of blood, prolonging the clotting time. Apixaban
(Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), enoxaparin (Lovenox),
fondaparinux (Arixtra), heparin, rivaroxaban (Xarelto), and warfarin (Coumadin)
are some examples of anticoagulants. Antiplatelet is a member of a class of
pharmaceutical drugs that decrease platelet aggregation and inhibit thrombus
formation. They are more effective in the arterial circulation compared
anticoagulants. Examples of antiplatelet include clopidogrel (Plavix),
dipyridamole/aspirin (Aggrenox), eptifibatide (Integrilin), prasugrel
(Effient), ticagrelor (Brilinta), and ticlodipine (Ticlid). Antihypertensives
are a class of drugs that are used to treat hypertension (high blood pressure).
Examples of antihypertensives include benazepril (Lotensin), captopril
(Capoten), enalapril (Vasotec), lisinopril (Zestril and Prinivil), perindopril
(Aceon), quinapril (Accupril), ramipril (Altace), and trandolapril
(Mavik).
Treatment-based
segmentation of the market covers tissue plasminogen activator (TPA) and
endovascular procedures. TPA is an enzyme involved in the breakdown of blood
clots and dissolves them. The endovascular procedure is surgery. Being
innovative, it is a less invasive procedure, popularly used for treating
problems affecting the blood vessels, such as an aneurysm, which is a swelling
or “ballooning” of the blood vessel. By types, the market has been segmented
into hemorrhagic strokes and ischemic stroke. The weakened blood vessel leakage
is called a hemorrhagic stroke. Its two categories are aneurysms and
arteriovenous malformations. Ischemic strokes occur because of an obstruction within
a blood vessel supplying blood to the brain.
Women Health Disease Diagnosis & Treatment
For More Information,
Please Visit @ Market Research Future
Comments
Post a Comment